These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Colquitt JL; Jones J; Tan SC; Takeda A; Clegg AJ; Price A Health Technol Assess; 2008 May; 12(16):iii-iv, ix-201. PubMed ID: 18462575 [TBL] [Abstract][Full Text] [Related]
11. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib]. Maier M; Feucht N; Huebner M; Lohmann C Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780 [TBL] [Abstract][Full Text] [Related]
13. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration. Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685 [TBL] [Abstract][Full Text] [Related]
14. Evolving European guidance on the medical management of neovascular age related macular degeneration. Chakravarthy U; Soubrane G; Bandello F; Chong V; Creuzot-Garcher C; Dimitrakos SA; Korobelnik JF; Larsen M; Monés J; Pauleikhoff D; Pournaras CJ; Staurenghi G; Virgili G; Wolf S Br J Ophthalmol; 2006 Sep; 90(9):1188-96. PubMed ID: 16929063 [TBL] [Abstract][Full Text] [Related]
15. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Gonzales CR; Retina; 2005; 25(7):815-27. PubMed ID: 16205558 [TBL] [Abstract][Full Text] [Related]
16. Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration. Williams AJ; Fekrat S Am J Ophthalmol; 2006 Oct; 142(4):683-4. PubMed ID: 17011868 [TBL] [Abstract][Full Text] [Related]
17. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. ; Apte RS; Modi M; Masonson H; Patel M; Whitfield L; Adamis AP Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689 [TBL] [Abstract][Full Text] [Related]
18. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Kourlas H; Schiller DS Clin Ther; 2006 Jan; 28(1):36-44. PubMed ID: 16490578 [TBL] [Abstract][Full Text] [Related]
19. Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration. Calvo-González C; Reche-Frutos J; Donate-López J; García-Feijoó J; Leila M; Fernández-Pérez C; Garcia-Sánchez J Br J Ophthalmol; 2008 Jan; 92(1):74-5. PubMed ID: 18156376 [TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Bressler NM; Arch Ophthalmol; 2001 Feb; 119(2):198-207. PubMed ID: 11176980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]